Correlation Between Lumos Pharma and Milestone Pharmaceuticals
Can any of the company-specific risk be diversified away by investing in both Lumos Pharma and Milestone Pharmaceuticals at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Lumos Pharma and Milestone Pharmaceuticals into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Lumos Pharma and Milestone Pharmaceuticals, you can compare the effects of market volatilities on Lumos Pharma and Milestone Pharmaceuticals and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Lumos Pharma with a short position of Milestone Pharmaceuticals. Check out your portfolio center. Please also check ongoing floating volatility patterns of Lumos Pharma and Milestone Pharmaceuticals.
Diversification Opportunities for Lumos Pharma and Milestone Pharmaceuticals
0.51 | Correlation Coefficient |
Very weak diversification
The 3 months correlation between Lumos and Milestone is 0.51. Overlapping area represents the amount of risk that can be diversified away by holding Lumos Pharma and Milestone Pharmaceuticals in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Milestone Pharmaceuticals and Lumos Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Lumos Pharma are associated (or correlated) with Milestone Pharmaceuticals. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Milestone Pharmaceuticals has no effect on the direction of Lumos Pharma i.e., Lumos Pharma and Milestone Pharmaceuticals go up and down completely randomly.
Pair Corralation between Lumos Pharma and Milestone Pharmaceuticals
Given the investment horizon of 90 days Lumos Pharma is expected to under-perform the Milestone Pharmaceuticals. But the stock apears to be less risky and, when comparing its historical volatility, Lumos Pharma is 4.4 times less risky than Milestone Pharmaceuticals. The stock trades about -0.13 of its potential returns per unit of risk. The Milestone Pharmaceuticals is currently generating about 0.28 of returns per unit of risk over similar time horizon. If you would invest 145.00 in Milestone Pharmaceuticals on August 29, 2024 and sell it today you would earn a total of 40.00 from holding Milestone Pharmaceuticals or generate 27.59% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Together |
| Strength | Weak |
| Accuracy | 100.0% |
| Values | Daily Returns |
Lumos Pharma vs. Milestone Pharmaceuticals
Performance |
| Timeline |
| Lumos Pharma |
| Milestone Pharmaceuticals |
Lumos Pharma and Milestone Pharmaceuticals Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Lumos Pharma and Milestone Pharmaceuticals
The main advantage of trading using opposite Lumos Pharma and Milestone Pharmaceuticals positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Lumos Pharma position performs unexpectedly, Milestone Pharmaceuticals can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Milestone Pharmaceuticals will offset losses from the drop in Milestone Pharmaceuticals' long position.| Lumos Pharma vs. Shattuck Labs | Lumos Pharma vs. Eliem Therapeutics | Lumos Pharma vs. Champions Oncology | Lumos Pharma vs. Century Therapeutics |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Instant Ratings module to determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance.
Other Complementary Tools
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Companies Directory Evaluate performance of over 100,000 Stocks, Funds, and ETFs against different fundamentals | |
| Bond Analysis Evaluate and analyze corporate bonds as a potential investment for your portfolios. | |
| Analyst Advice Analyst recommendations and target price estimates broken down by several categories | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges |